Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HFA-152A propellant · 1 trial · 1 indication
FEV1 is defined as the volume of air that can be forced out in one second, after taking a deep breath and measured using spirometry. Baseline is defined as the latest pre-dose assessment with a non-missing value including those from unscheduled visits.
| Arm | Type | Description |
|---|---|---|
| HFA-152A propellant followed by HFA-134A propellant | EXPERIMENTAL | - |
| HFA-134A propellant followed by HFA-152A propellant | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| HFA-152A propellant | DRUG | HFA-152A propellant is administered via oral inhalation |
| HFA-134A propellant | DRUG | HFA-134A propellant is administered via oral inhalation |
Inclusion Criteria: Participants are eligible to be included in the study if all the following criteria apply: * Male or female; females may be of childbearing potential, of nonchildbearing potential, or postmenopausal. * Participant must be 18 to 45 years of age inclusive, at the time of screenin...
HFA-152a propellant is an investigational small molecule being studied for use in asthma. It is a propellant intended for pressurized inhalers, and a clinical trial has assessed its potential for airway sensitivity reactions in adults with mild asthma.
HFA-152a propellant does not target a specific molecular target. It is a propellant, a substance used to deliver medication from a pressurized inhaler. Its role is to serve as a carrier for asthma medications, rather than to interact with a biological target.
HFA-152a propellant is being developed by GSK plc, a biopharma company traded on the New York Stock Exchange under the ticker GSK. GSK is conducting clinical research on this propellant for use in pressurized inhalers for asthma.
HFA-152a propellant is in Phase 1 clinical development. It is an investigational product and has not been approved by regulatory authorities. A Phase 1 trial has been completed to assess its safety and tolerability in adults with mild asthma.
HFA-152a propellant has one completed clinical trial, NCT06702462, titled "A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma." This Phase 1 trial enrolled 20 participants in the United States.
No, HFA-152a propellant is not the same as HFA-134a. In clinical trial NCT06702462, HFA-152a is the test propellant and HFA-134a is the reference propellant. The study compares the two to assess the potential for airway sensitivity reactions in adults with mild asthma.